UCB’s approval spree rolls on with FDA nod for Zilbrysq, its 2nd drug for myasthenia gravis kdunleavy Wed, 10/18/2023 – 11:17 More: UCB's approval spree rolls on with FDA nod for Zilbrysq, its 2nd drug for myasthenia gravis Source: fierce
read moreTakeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee fkansteiner Wed, 10/18/2023 – 11:09 More: Takeda ponies up €130M to settle tax linked to distant AbbVie-Shire breakup fee Source: fierce
read moreUCB’s blockbuster hopeful Bimzelx overcomes manufacturing hurdles to win FDA nod zbecker Wed, 10/18/2023 – 10:51 More: UCB's blockbuster hopeful Bimzelx overcomes manufacturing hurdles to win FDA nod Source: fierce
read moreFishawack Health transforms into Avalere Health, drawing inspiration from starlings badams Wed, 10/18/2023 – 09:44 More: Fishawack Health transforms into Avalere Health, drawing inspiration from starlings Source: fierce
read moreUK researchers can apply to receive a share of £3m to set up transdisciplinary networks More: UKRI awards £10m in funding to tackle antimicrobial resistance Source: News
read moreAround 700 people in the UK could benefit from the new treatment More: NICE recommends Roche’s Columvi for advanced lymphoma in UK Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals